دانلود رایگان مقاله لاتین ویروسی پلیمر اسید نوکلئیک برای درمان هپاتیت b و d از سایت الزویر
عنوان فارسی مقاله:
پلیمرهای اسید نوکلئیک: طیف گسترده فعالیت ضد ویروسی، بهینه سازی و مکانیسم های ضد ویروسی برای درمان هپاتیت B و هپاتیت D
عنوان انگلیسی مقاله:
Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection
سال انتشار : 2016
برای دانلود رایگان مقاله ویروسی پلیمر اسید نوکلئیک برای درمان هپاتیت b و d اینجا کلیک نمایید.
مقدمه انگلیسی مقاله:
1. Introduction
Hepatitis B virus (HBV) has affected more than 2 billion people worldwide, with recent estimates indicating that 248 million of these individuals still have chronic HBV infection (Schweitzer et al., 2015). The life cycle and molecular biology of HBV infection have been previously described by Gish et al., 2015 in this review series. Complications arising from chronic hepatitis B include the development of liver fibrosis and hepatocelulluar carcinoma (Gish et al., 2015) necessitating therapy to control infection. The disappearance of the hepatitis B surface antigen protein (HBsAg) from the blood (HBsAg loss) is considered the best prognostic indicator for the establishment of control over HBV infection which can endure in the absence of therapy (Frenette and Gish, 2009; Moucari et al., 2009). While treatment with HBV polymerase inhibitors like entecavir and tenofovir disoproxil fumarate suppress HBV DNA and control the onset of liver disease, they rarely lead to HBsAg loss and require continual therapy (Chang et al., 2006; Lai et al., 2006; Marcellin et al., 2008). Treatment with immunotherapies like pegylated interferon can achieve HBsAg loss but only in a small fraction of patients and combination treatment with immunotherapy and HBV polymerase inhibitors offers only small improvements in the rates of HBsAg loss on therapy (Lau et al., 2005; Marcellin et al., 2008, 2016). As such, there is a need for more effective treatments for CHB infection, particularly those therapies which can increase the incidence of HBsAg loss during therapy. Nucleic acid polymers (NAPs) are the most recently characterized member of the antiviral polymer family of compounds which share the broad spectrum antiviral activity of this class of antiviral compounds. Importantly, NAPs appear to have a unique ability to block the secretion of HBsAg from HBV-infected hepatocytes not observed with other antiviral polymers. NAPs also belong to another class of compounds, phosphorothioate oligonucleotides (PS-ONs), which can be safely given to human subjects where they naturally accumulate in the liver and enter into hepatocytes. This article provides an overview of the mechanistic properties of antiviral polymers, the general pharmacokinetic properties of PSONs and a review of the discovery, characterization and optimization of NAPs for clinical use and their antiviral effects against HBV and HDV infection in vivo and in human subjects.
برای دانلود رایگان مقاله ویروسی پلیمر اسید نوکلئیک برای درمان هپاتیت b و d اینجا کلیک نمایید.
کلمات کلیدی:
Understanding early serum hepatitis D virus and hepatitis B surface ... onlinelibrary.wiley.com/doi/10.1002/hep.27357/full by J Guedj - 2014 - Cited by 16 - Related articles Oct 27, 2014 - There is little information on the early kinetics of hepatitis delta virus (HDV) and ... Treatment of HDV infection has been notoriously difficult. ..... is consistent with the use of HBsAg kinetics to optimize HDV treatment duration. Optimization therapy for the treatment of chronic hepatitis B - NCBI - NIH https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) by EQ Chen - 2014 - Cited by 11 - Related articles May 21, 2014 - The key points in this optimization therapy are to initiate antiviral therapy with an ... An estimated 350 million people are infected with hepatitis B .... in HBsAg in HBeAg negative patients infected by HBV genotype D. However, ... Molecular and clinical aspects of hepatitis D virus infections - NCBI - NIH https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) by ES Dastgerdi - 2012 - Cited by 16 - Related articles Jun 12, 2012 - Further clinical trials are underway to optimize treatment strategies for delta hepatitis. Keywords: Hepatitis D virus, Hepatitis B virus, Delta ... Therapeutic Strategies and New Intervention Points in Chronic ... https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) by Z Guo - 2015 - Cited by 3 - Related articles Aug 18, 2015 - Chronic hepatitis delta virus infection (CHD) is a condition arising .... Treatment of acute co-infection of HDV/HBV is same as the treatment of acute hepatitis B ... as effective new therapies emerge and their regimens optimized. [PDF]Nucleic acid polymers: Broad spectrum antiviral activity, antiviral ... iranarze.ir/wp-content/uploads/2016/10/E1100.pdf Jul 9, 2016 - mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Andrew Vaillant. Replicor Inc., 6100 Royalmount Avenue ... Hepatitis B Virus: Advances in Research and Treatment: 2011 Edition: ... https://books.google.com/books?isbn=1464942455 2012 - Medical ... evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a ... clarify the interplay between HDV and hepatitis B virus (HBV) in chronic infection. ... Pisa: New approaches to optimize treatment responses in chronic hepatitis B ... Nucleic acid-based polymers effective against hepatitis B Virus ... www.nature.com › Scientific Reports › Articles › Article Mar 8, 2017 - ... antiviral activity of NAPs optimized to treat HBV infection in patients ..... optimization for the treatment of hepatitis B and hepatitis D infection . Publication: Nucleic acid polymers: Broad spectrum antiviral activity ... https://www.researchgate.net/.../305111462_Nucleic_acid_polymers_Broad_spectrum_a... Feb 17, 2017 - ... spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection on ResearchGate.
